A major breakthrough in cancer immunotherapy was the discovery that immunomodulation of Tcells’ through immune check-points, such as programmed death 1 and its ligand (PD1-PDL1) [6, 30] and cytotoxic T-lymphocyte antigen 4 (CTLA4) [23], induces immune evasion of cancer cells [16]. Here, CD274 is linked to cancer.